Page last updated: 2024-12-05
cotarnine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
cotarnine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6715 |
| CHEMBL ID | 4745550 |
| CHEBI ID | 166583 |
| SCHEMBL ID | 679713 |
| MeSH ID | M0045839 |
Synonyms (43)
| Synonym |
|---|
| 4-methoxy-6-methyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-5-ol |
| 82-54-2 |
| CHEBI:166583 |
| nsc-121978 |
| 59760-32-6 |
| nsc121978 |
| cotarnine |
| 1,3-dioxolo(4,5-g)isoquinolin-5-ol, 5,6,7,8-tetrahydro-4-methoxy-6-methyl- |
| cotarnin |
| einecs 201-429-8 |
| 5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-ol |
| brn 0022879 |
| AKOS005605723 |
| STK693623 |
| 4-methoxy-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-ol |
| 79v56tdi6g , |
| 4-27-00-06448 (beilstein handbook reference) |
| unii-79v56tdi6g |
| FT-0624071 |
| (+/-)-cotarnine |
| cotarnine [mi] |
| cotarnine, (+/-)- |
| cotarnine [who-dd] |
| SCHEMBL679713 |
| 5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-ol |
| PAPMYQLKLNRZIR-UHFFFAOYSA-N |
| 4-methoxy-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-ol # |
| 4-methoxy-6-methyl-7,8-dihydro-5h-[1,3]dioxol[4,5-g]isoquinolin-5-ol |
| 1,3-dioxolo[4,5-g]isoquinolin-5-ol,5,6,7,8-tetrahydro-4-methoxy-6-methyl- |
| DTXSID80274484 |
| sr-01000884006 |
| SR-01000884006-1 |
| mfcd00190616 |
| 99781-53-0 |
| 4-methoxy-6-methyl-2h,5h,6h,7h,8h-[1,3]dioxolo[4,5-g]isoquinolin-5-ol |
| NS-03227 |
| Q27266783 |
| 4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-ol |
| XC160978 |
| 4-methoxy-6-methyl-5,6,7,8-tetrahydro-2h-[1,3]dioxolo[4,5-g]isoquinolin-5-ol |
| DTXSID40871559 |
| CHEMBL4745550 |
| EN300-302336 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| "Noscapine, a phthalideisoquinoline alkaloid derived from opium, has been used as an oral anti-tussive agent and has shown very few toxic effects in animals or humans." | ( Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Archer, DR; Grossniklaus, HE; Joshi, HC; Kapp, JA; Ke, Y; Ye, K, 2000) | 0.31 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| isoquinolines | A class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 52.11
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (52.11) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||